P-gp and BCRP can eliminate from cancer cells a wide variety of structurally and functionally unrelated anticancer agents, including epipodophyllotoxins, anthracyclines, vinca alkaloids, bisantrene, colchicine, taxanes, imatinib, saquinavir, camptothecins, thiopurines, actinomycin D, methotrexate, and mitoxantrone to the extracellular space, reducing intracellular drug accumulation [14,15,18,19,20]. The gene discussed is PGP; the disease is cancer.